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Abstract
Background: Chloroquine resistance (CR) decreased after the removal of chloroquine from national treatment
guidelines in Malawi, Kenia and Tanzania. In this investigation the prevalence of the chloroquine resistance (CQR)
conferring mutant pfcrt allele and its associated chromosomal haplotype were determined before and after the change
in Gabonese national treatment guidelines from chloroquine (CQ) to artesunate plus amodiaquine (AQ) in 2003.
Methods: The prevalence of the wild type pfcrt allele was assessed in 144 isolates from the years 2005 - 07 by PCR
fragment restriction digest and direct sequencing. For haplotype analysis of the chromosomal regions flanking the
pfcrt locus, microsatellite analysis was done on a total of 145 isolates obtained in 1995/96 (43 isolates), 2002 (47
isolates) and 2005 - 07 (55 isolates).
Results: The prevalence of the mutant pfcrt allele decreased from 100% in the years 1995/96 and 2002 to 97% in
2005 - 07. Haplotype analysis showed that in 1995/96 79% of the isolates carried the same microsatellite alleles in a
chromosomal fragment spanning 39 kb surrounding the pfcrt locus. In 2002 and 2005 - 07 the prevalence of this
haplotype was 62% and 58%, respectively. Pfcrt haplotype analysis showed that all wild type alleles were CVMNK.
Conclusion: Four years after the withdrawal of CQ from national treatment guidelines the prevalence of the
mutant pfcrt allele remains at 97%. The data suggest that the combination of artesunate plus AQ may result in
continued selection for the mutant pfcrt haplotype even after discontinuance of CQ usage.
Keywords: chloroquine resistance, chloroquine sensitivity, microsatellite analysis, haplotype analysis, artesunate plus
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Background
The evolution of CQR has been a major obstacle to glo-
bal public health [1]. CQR reached Africa in the late
seventies and reached a high prevalence across the con-
tinent over the following decade [2]. Malawi was the
first African country to discontinue the use of CQ in
1993 [3]. Interestingly, the prevalence of the resistant
pfcrt allele 76T decreased drastically from 85% to 13%
within the following eight years [3,4]. In 2005, a clinical
trial showed a 100% efficacy of CQ for treatment of
uncomplicated Plasmodium falciparum malaria in chil-
dren [5]. Recently, Kenya and Tanzania have also
reported a decline in CQR after replacement of CQ by
sulphadoxine-pyrimethamine (SP), however, this decline
occurred at a much slower rate than in Malawi [6,7].
* Correspondence: Matthias.frank@uni-tuebingen.de
† Contributed equally
1Institute of Tropical Medicine, University of Tübingen, Wilhelmstr.27, 72074
Tübingen, Germany
Full list of author information is available at the end of the article
Frank et al. Malaria Journal 2011, 10:304
http://www.malariajournal.com/content/10/1/304
© 2011 Frank et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.The genetic cause of CQR was found to be a single point
mutation changing the amino acid lysine (K) to threonine
(T) at position 76 in the gene coding for the P. falciparum
CQ resistance transporter (pfcrt) [8-10]. This mutation
arose only in a small number of founder locations, from
where the resistant parasites spread worldwide. As a con-
sequence, the variability of the chromosomal regions
flanking the pfcrt gene on chromosome 7 is strongly
reduced in resistant parasites, a phenomenon referred to
as selective sweep [11]. The chromosomal haplotype - a
characterization of this part of the chromosome, assessed
either by SNP or microsatellite analysis - is, therefore,
highly conserved in resistant parasites and specific for the
respective founder locations. In contrast, sensitive para-
sites generally have very diverse haplotypes [11,12].
In Gabon, CQ use was officially discontinued in 2003
and replaced by the combination of artesunate and AQ.
B e f o r et h ec h a n g ei nn a t i o n a l treatment guidelines the
prevalence of the mutant pfcrt allele 76T was repeatedly
measured to be 100% [13-15]. The goal of this study is
to investigate if this change was associated with a return
of the wild type pfcrt allele - as has been observed in
other African countries - and if it affected genetic diver-
sity in the surrounding chromosomal areas.
Methods
Study site and population
All samples were taken from clinical studies conducted
at the Albert-Schweitzer-Hospital in Lambaréné, Gabon.
Malaria in Lambaréné is hyperendemic with stable
transmission throughout the year, the predominant spe-
cies is P. falciparum [16]. Patients had been recruited in
Lambaréné and surroundings (radius approx. 60 km).
Informed consent had been obtained by all patients or
their guardians and all studies had been approved by
the Ethics Committee of the International Foundation of
the Albert Schweitzer Hospital. For the 1995/96 cohort,
samples from the 1/95C study were analysed [17]. The
2002 cohort consisted of samples from the 2002 case
control study [15,18]. For the years 2005 - 07 samples
were obtained from the Antigenic Diversity Study
[19,20], the Ferroquine Tolerance Trial [21], the IPTi
Study [22,23] and the SP Efficacy Trial [24].
DNA extraction
Parasite DNA was extracted either from whole blood
samples or from dried filter blood spots using the
QIAamp
® DNA Mini Kit or DNA Blood Mini Kit (Qia-
gen, Hilden, Germany) according to the manufacturer’s
protocol. Extracted DNA was stored at -20°C.
Polymerase chain reaction and sequencing
Polymerase chain reaction (PCR) was carried out using
2.5 mM MgCl2, 0.2 mM denucleoside triphosphates, 0.5
μM forward and reverse primer, 1.5 U Taq polymerase
and 5 μl DNA in a total volume of 50 μl. In case of
nested PCRs 5 μl PCR product of the first amplification
step was used as template in the second step. PCR
reagents were obtained from Qiagen, primers were
ordered from Operon (Cologne, Germany). Reactions
were run in a Biometra Uno II Thermal Cycler (Biome-
tra, Goettingen, Germany), a MyCycler Thermal Cycler
(Bio-Rad, Munich, Germany) and a MJ Research PTC-
200 (GMI, Ramsey, USA). PCR products were stained
with SYBR Green (Biozym, Hess. Oldendorf, Germany)
and run on a 1.5% agarose gel. PCR products submitted
to sequencing were cut out of the gel, extracted and
purified using the NucleoSpin Extract II Kit (Machery-
Nagel, Dueren, Germany) according to the manufac-
turer’s protocol. This was followed by a sequencing PCR
using 1/10 BigDye Terminator (Applied Biosystems,
Warrington, UK) and approx. 1.5 ng DNA/100 bp. 25
cycles were run consisting of melting at 94°C for 10 sec,
annealing at 50°C for 5 sec and elongation at 60°C for 4
min. Obtained PCR products were purified using Sepha-
dex 96-well plates (GE Healthcare, Little Chalfont, UK)
and sequenced by a Abi Prism 3000 Gene Analyzer
(Applied Biosystems). Sequences were displayed with
the BioEdit software (Ibis Biosciences, Carlsbad, USA).
Detection of pfcrt mutations by restriction digest and
sequencing
CQR of isolates was determined by detection of the
mutant or wild type allele of the pfcrt gene at position
76. The CQR conferring mutation K76T as well as
seven other resistance associated mutations (M74I,
N75E, A220S, Q271E, N326S, I356T, R371I) were
detected using a method consisting of a nested PCR fol-
lowed by mutation specific restriction digestion as
described by Djimde et al [25]. The mutations M74I
and N75E were directly detected via PCR product
sequencing.
Haplotype analysis
The chromosomal haplotype was defined as the specific
combination of the alleles of the following six microsa-
tellite markers: PE14D (distance from the pfcrt gene -45
kb), B5M77 (-18 kb), 3E7 (-11 kb), 9B12 (+2 kb), 7A11
(+21 kb) and PE14F (+57 kb). Additionally, the microsa-
tellite B5M47 (-0 kb) was analysed in several isolates of
the years 2005 - 07 but not taken into account for the
haplotype analysis. The position of the individual micro-
satellites relative to pfcrt is calculated based on their
coordinates on Chromosome 7 of the 3D7 genome
strain (http://www.plasmodb.org). These differ some-
what from the originally reported distances by Wootton
et al [11]. Alleles were determined as differences in
repeat length. The repeat sequence motifs of the
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(TAA), B5M77 (TA), 3E7 (TA)/(T)/(TA), 9B12 (TA),
7A11 (TTATA), PE14F (TAA). In case of multiple infec-
tions only samples with a clear dominance of one
microsatellite allele in the sequence ferrogram were
included for further analysis [12].
Microsatellite markers were amplified via PCR and
sequenced. Primers and conditions were adapted from
Su et al [26] but resulted in suboptimal amplification in
field isolates. Therefore conditions had to be modified
for all microsatellites and in most cases a nested PCR
approach had to be implemented (see Additional file 1).
The strains 3D7, Dd2 and FCR3 were used as positive
PCR controls. The consistency of primers and condi-
tions was verified by sequencing of the PCR amplifica-
tion products of the control strains and comparing the
obtained microsatellite sequences with the known
sequences deposited in the NCBI database, which always
showed a perfect match of the repeat lengths.
Chromosomal haplotype studies were done on 171
resistant samples from the years 1995 - 2007. Successful
sequencing of the full set of microsatellites was achieved
in 132 samples. In 145 samples at least the inner four
microsatellites (B5M77, 3E7, 9B12, 7A11) covering a
chromosomal fragment of approximately 40 kb could be
sequenced. These samples consisted of 43 samples from
the 1995/96 cohort, 47 samples of the 2002 cohort and
55 samples of the 2005 - 7 cohort. All sequences were
submitted to Genbank. Individual samples can be identi-
fied through their study specific label, consisting of a
study specific combination of letters and an isolate spe-
cific running number, as indicated below: 1/95C study
(M or S, followed by a number, i.e. M1), 2002 case con-
trol study (N followed by a number, i.e. N1), Antigenic
Diversity Study (three individual letters, i.e. MOA), the
Ferroquine Tolerance Trial (TDU or FED or TDR, fol-
lowed by a number, i.e. TDU1), IPTi Study (IP followed
by a number, i.e. IP1), SP Efficacy Trial (SP followed by
a number, i.e. SP1). Genbank accession numbers are:
3E7 sequences: HQ417163 -HQ417327, 7A11 sequences:
HQ417328 - HQ417497, 9B12 sequences: HQ417498-
HQ417655, B5M77 sequences: HQ417656 - HQ417824,
PE14D sequences: HQ417825 - HQ417986, PE14F
sequences: HQ417987-HQ418152.
msp2 genotyping
50 isolates from all four studies of the years 2005 - 07
were further characterized by sequencing of the central
region of the merozoite surface protein 2 (msp2) gene.
Primers and conditions for an allele specific nested PCR
were as described by [27]. MSP2 1
st step: forward pri-
mer F1 ATGAAGGTAATTAAAACATTGTCTAT-
TATA and reverse primer F2 ATATGGCAAAAGAT
AAAACAAGTGTTGCTG, 94°C for 5 min, followed by
30 cycles of 94°C for 10 sec, 57°C for 30 sec, 72°C for
30 sec, and a final extension step of 72°C for 2 min.
MSP2 2
nd step FC allele: forward primer FC27 F2
GCAAATGAAGGTTCTAATACTAATAG and reverse
primer FC27 R2 GCTTTGGGTCCTTCTTCAGTT-
GATTC, MSP2 2
nd step 3D7 allele: forward primer 3D7
F2 GCAGAAAGTAAGCCTTCTACTGGTGCT and
reverse primer 3D7 R2 GATTTGTTTCGGCATTAT-
TATGA. PCR was carried out using the following con-
ditions 94°C for 5 min, followed by 40 cycles of 94°C for
10 sec, 57°C for 30 sec, 72°C for 30 sec, and a final
extension step of 72°C for 2 min.
Statistical analysis
Conservation of any marker or haplotype was defined as
the prevalence of the dominant allele. Development of
the degree of conservation over the years was analysed
by logistic regression. A chi-square test was applied for
assessment of significance. Allele diversity was described
by the expected heterozygosity He using the formula: He
= [n/(n-1)][1-Σpi
2]w i t hn being the number of isolates
and pi the frequency of the ith allele [28]. Development
of He over the years was analysed by linear regression,
an F test was applied for assessment of significance. In
all applied tests p-values < 0.05 were regarded as
significant.
Results
Prevalence of the mutant and wild type pfcrt allele before
and after the withdrawal of chloroquine
In order to display the prevalence of the mutant pfcrt
allele after 2003, 144 samples from the years 2005 - 07
were screened for the CQR conferring mutant 76T pfcrt
allele. The restriction digest revealed only one sample
with a wild type 76K pfcrt allele, thus a genetically sensi-
tive isolate, in 90 samples from the years 2005/06 (1%)
and three isolates with the wild type 76K pfcrt allele in
54 samples from 2007 (6%) (of the wild type isolates
three were monoinfections and one was a mixed infec-
tion). Overall the prevalence of the mutant 76T pfcrt
allele remained at 97% after the withdrawal of chloro-
quine from national treatment guidelines. Previous ana-
lysis of 151 samples from the years 1995/96 and 2002
had shown a prevalence of 100% for the mutant 76T
allele [13-15]. For this investigation an additional 64
samples of these studies were analysed. The mutant 76T
pfcrt allele was detected in all samples. Thus, in total all
215 analysed samples from the years 1995/96 and 2002
carried the mutant 76T pfcrt allele, confirming the very
high prevalence of the mutant pfcrt allele in this area
prior to the change in national treatment guidelines (see
Table 1).
Pfcrt haplotype analysis was conducted in the three
wild type isolates that were monoinfections and 48
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7. Sequencing of the three monoinfections showed that
all carried the original wild type pfcrt haplotype
CVMNK at the codons 72-76 and AQNIR at the codons
220, 271, 326, 356, 371. The reappeared wild type pfcrt
allele thus did not result from a simple back mutation
from T to K at codon 76. Sequencing of 48 randomly
picked mutant isolates from the years 2005-7 showed
that they uniformly carried the CVIET haplotype at the
codons 72-76.
Chromosome 7 haplotype characterization of mutant and
wild type isolates
To assess the effect of chloroquine pressure on the
chromosomal haplotype, microsatellite allele analysis
was initally performed on isolates from 1995/6. For
characterization of the chromosome fragment surround-
ing the pfcrt gene six microsatellite markers were
sequenced (PE14D, B5M77, 3E7, 9B12, 7A11, PE14F)
covering a chromosomal fragment of approximately 100
kb (see Figure 1). Analysis of the obtained haplotypes
revealed the presence of two most prevalent haplotypes
in 1995/96. One haplotype was identical to the haplo-
type of the resistant lab strain FCR3 [11] (assumed to
represent the dominant resistant haplotype in Africa
and differing from Dd2 at the microsatellite 7A11) at all
six analysed microsatellites and was found in 21% of the
samples. The other haplotype, termed “Lamba”,s h o w e d
a different allele at the most centromeric marker PE14F
(see Figure 1) and was prevalent in 37%. Together we
defined these two haplotypes as the dominant local
resistant haplotypes.
To assess whether the newly appeared pfcrt sensitive
isolates from the years 2005-7 represented immigrated
strains or local formerly resistant strains that had reac-
quired the wild type pfcrt allele, haplotype analysis of
the wild type isolates was performed. Haplotype analysis
was possible in the three monoinfections (samples SP15,
SP21, TDU28) of the four wild type isolates. The isolates
SP21 and TDU28 carried haplotypes with no resem-
blance to the dominant local resistant haplotypes. In
contrast, the haplotype of isolate SP15 was identical to
the dominant local resistant haplotypes at the most telo-
meric microsatellites PE14D and B5M77 and only
started to diverge at microsatellite 3E7, approximately
11 kb upstream of the pfcrt l o c u s( s e eF i g u r e1 ) .T h i s
suggested that SP15 might have resulted from a back-
cross of a wild type pfcrt allele into a local resistant
isolate.
Prevalence of the dominant local resistant resistant
haplotypes before and after the withdrawal of
chloroquine
The prevalence of the dominant local resistant haplo-
types was assessed in 1995/96 and 2002, before the
withdrawal of chloroquine from national treatment
guidelines, as well as in 2005-7. The dominant local
resistant haplotypes maintained a high prevalence at all
Table 1 Prevalence of the mutant and wild type pfcrt
allele before and after the withdrawal of chloroquine
from national treatment guidelines (2003)
1995-2002 2005-07
no. of samples 215 144
no. with mutant 215 (100%) 141 (97%)
no. with wild type 0 (0%) 4 (3%)
Mutant: pfcrt 76 T
Wild type: pfcrt 76 K
Figure 1 Haplotype analysis of resistant and sensitive parasites. The two most frequent local resistant haplotypes from the year 1995/6 are
displayed. One of the haplotypes is identical to the FCR3 haplotype and represented 21% of all haplotypes analysed in 1995/6. The other
haplotype (denoted “Lamba”) represented 37% of all haplotypes in 1995/6. The haplotypes of the three sensitive monoinfections SP15, SP21 and
TDU28 from the years 2005 - 7 are represented in the lower part of the figure. Alleles identical to the local resistant haplotypes are shaded in
light grey, differing alleles in dark grey. Samples SP21 and TDU28 carry completely different chromosome 7 haplotypes, suggesting that they
represent reintroduced sensitive parasites. In contrast SP15 carries the same alleles as the local resistant haplotypes at the microsatellite PE14D
and B5M77 and subsequently starts to diverge. This suggests a backcross of the sensitive pfcrt allele. Sequencing of the marker 9B12 in the
sensitive isolate SP21 was unsuccessful. Haplotypes are represented by indicating the number of repeats at each microsatellite. The pfcrt
haplotype at codons 72-76 is also displayed.
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96 to 31% in 2002 and 33% in 2005 - 07 (p = 0.01, see
Table 2) was noticeable. However, it is striking that the
observed development towards lesser conservation took
place entirely between 1995/96 and 2002 - thus before
the withdrawal of CQ - while no significant change in
conservation could be observed between 2002 and 2005
- 07. Besides the dominant local resistant resistant hap-
lotypes, multiple other individual haplotypes were iden-
tified. Most of these haplotypes, however, were found
only once in the examined population. The total num-
ber of unique haplotypes present in the parasite popula-
tion increased from 18 (including the two dominant
haplotypes) in 1995/96 to 28 in 2002 and stayed at 28
in 2005 - 07.
To assess genetic change in the chromosomal areas
immediately adjacent to the pfcrt locus a local “inner”
haplotype was defined as the chromosomal fragment
defined by the four microsatellites B5M77, 3E7, 9B12,
7A11, covering a region of approximately 40 kb around
the pfcrt locus. This revealed that in 1995/96 79% of the
analysed isolates carried one identical haplotype in this
chromosomal region. In analogy to the six-microsatel-
lite-haplotype, the prevalence of this dominant local
“inner” haplotype remained relatively high throughout
the years, but showed a statistically significant decrease
to 62% in 2002 and 58% in 2005 - 07 (p =0 . 0 3 ,s e e
Table 3). Again, the decrease in conservation was most
pronounced between 1995/6 and 2002, before the
change in national treatment guidelines.
To evaluate the propensity for genetic change at the
individual microsatellite markers, the change in conser-
vation from 1995/6 to 2005 - 07 was evaluated. This
revealed a significant decrease in conservation at the
two most centromeric microsatellites 7A11 (p =0 . 0 4 )
and PE14F (p = 0.02) while the other microsatellite mar-
kers remained conserved.
In order to assess the degree of genetic diversity at the
individual microsatellites over the years, their expected
heterozygosity He during the different time periods (see
Figure 2) was determined. As expected, He was smallest
at the microsatellites directly adjacent to the pfcrt locus
and largest at the most distant microsatellites. During
all time periods He increased with increasing distance
from the pfcrt locus. Furthermore, He was higher at the
centromeric microsatellites 9B12, 7A11 and PE14F com-
pared to the telomeric microsatellites 3E7, B5M77 and
PE14D, again suggesting a higher degree of genetic
variability in the centromeric microsatellites. A trend
towards increasing diversity over time was apparent for
the two most centromeric microsatellites 7A11 and
PE14F, however this was not statistically significant.
Genetic diversity at the msp2 gene
The analysis suggested that the genetic sweep on chro-
mosome 7 persisted in the local parasite population
despite the removal of CQ from the national treatment
guidelines. To estimate the potential diversity in the
Lambaréné parasite population, the expected heterozyg-
osity at the locus coding for MSP2, a surface antigen
with a presumably high diversity was also determined.
The msp2 locus from 50 isolates of the years 2005 - 07
was PCR amplified and the respective 3D7 (30) and
FC27 (40) fragments were sequenced. A total of 48 dif-
ferent alleles were identified. The He for the msp2 locus
was calculated to be 0.98. In comparison, the mean
genomic He of African P. falciparum parasites was
assessed to be 0.76 - 0.8 [28]. Of the microsatellites ana-
lysed in the 2005 - 07 population only the least con-
served marker PE14F had a He within that range (0.76).
Contrasting, the microsatellite B5M47 lying directly
adjacent to the pfcrt locus had a He of 0.11 (see Table
4). Taken together, this shows that the potential for
genetic diversity is very high in this population and
highlights the high degree of genetic conservation sur-
rounding the mutant pfcrt gene on chromosome 7.
Discussion
This is the first report analysing the effect of the with-
drawal of CQ from the national treatment guidelines in
2003 on the prevalence of the mutant pfcrt allele in
Lambaréné, Gabon. Prior to the change in national
treatment policy the prevalence of the mutant pfcrt
allele 76T had been 100% [13,14]. However, even in the
years 2005 - 07 the level of CQR was still as high as
97%. Thus the decrease of CQR after discontinuance of
CQ use observed in Gabon is much smaller compared
to the development in Malawi where resistance
decreased within eight years from 85% to 13% [3,4], as
well as compared to other African countries such as
Kenya [7] and Tanzania [6] where recent reports also
documented a decrease in CQR from 95% to 60% and
94% to 70% respectively, after national CQ stops. What
explanations can be invoked to explain the differences
in the decline of CQR in these countries and Gabon?
The resurgence of CQS in Malawi, Kenya and Tanza-
nia was observed after changes in national treatment
Table 2 Prevalence of the local resistant haplotypes (100
kb) over the years
1995/
96
2002 2005-
07
no. of samples 38 45 49
no. of samples with local haplotypes
(~100 kb)
22
(58%)
14
(31%)
16
(33%)
no. of samples with other haplotypes
(~100 kb)
16
(42%)
31
(69%)
33
(67%)
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its national treatment guidelines from CQ to the combi-
nation of artesunate plus AQ. AQ is structurally related
to CQ with both belonging to the group of 4-aminoqui-
nolines. A recent report from Ghana analysed the preva-
lence of the mutant pfcrt allele after a change in
national treatment guidelines from CQ to artesunate
and AQ. The authors observed a decrease in the preva-
lence of the mutant pfcrt allele only in the northern part
of the country, raising the question if this effect truly
represented a national trend [29]. In contrast, a recent
report from the Gabonese region of Franceville showed
no change in the prevalence of the mutant pfcrt allele
after the change in national treatment guidelines [30].
Data from clinical trials and the 7G8xGB4 and
HB3xDd2 genetic crosses clearly suggest that AQ
strongly selects for the resistance conferring mutant
pfcrt allele [31,32]. Analysis of progeny of the 7G8xGB4
genetic cross showed that the South American pfcrt
haplotype SVMNT at the codons 72-76 is associated
with high level resistance against monodesethylamodia-
quine, the active metabolite of AQ. Reports from Angola
[ 3 3 ]a n dT a n z a n i a[ 3 4 ]h a v es h o w nt h ep r e s e n c eo ft h e
SVMNT pfcrt haplotype following the use of artesunate
and AQ or the single use AQ, suggesting that AQ may
select for this haplotype [35]. However, none of the 48
randomly sequenced mutant pfcrt alelles from the years
2005 - 07 carried the SVMNT haplotpype in this analy-
sis of the Lambaréné parasite population. In view of the
high conservation of the chromosomal regions flanking
the pfcrt gene even in 2005 - 07 this may simply reflect
the continued selection of the most abundant pfcrt hap-
lotype CVIET. The introduction of the SVMNT haplo-
type may thus be influenced by the specific
characteristics of local parasite populations. Taken
together the data suggest that in Gabon the introduction
of artesunate plus AQ may have selected for continued
conservation of the mutant pfcrt locus.
Interestingly, a decrease in conservation of the local
resistant chromosomal haplotypes was observed between
1995/96 and 2002, prior to the removal of CQ from the
national treatment guidelines. A similar phenomenon
was observed in Kenya, where CQR started to decline
prior to the official change in national treatment guide-
lines, possibly as a consequence of declining use due to
decreased clinical effectiveness. Similarly, local treatment
guidelines at the Albert Schweitzer Hospital were
already changed in 1994 - from CQ to SP. A decrease in
CQ pressure might thus have contributed to more
genetic diversity surrounding the pfcrt locus, however
the resurgence of CQS might have been precluded due
to the continued use of CQ in the surrounding areas.
Table 3 Prevalence of “inner” haplotype (40 kb) over the years
1995/96 2002 2005-07
no. of samples 43 47 55
no. of samples with local “inner” haplotype (~40 kb) 34 (79%) 29 (62%) 32 (58%)
no. of samples with other “inner” haplotypes (~40 kb) 9 (21%) 18 (38%) 23 (42%)
Figure 2 Expected heterozygosity around the pfcrt locus before and after the removal of chloroquine from national treatment
guidelines. The expected heterozygosity He is shown for each microsatellite in the resistant populations of the years 1995/96 (diamonds), 2002
(squares) and 2005-07 (triangles). On the x-axis the distance [kb] from the pfcrt locus is given. During all time periods He increased with
increasing distance from the pfcrt locus but was higher at the centromeric microsatellites compared to the telomeric microsatellites.
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resistant haplotypes from 1995 to 2002 and by the
decrease in prevalence of the most common “local resis-
tant haplotypes”.
What could be the mechanism that led to the reap-
pearance of the wild type pfcrt allele? None of seven
point mutations in the pfcrt gene commonly found in
CQR strains from Africa and Asia [11,36] were present
in any of the genetically sensitive isolates, who thus
appear to be genuine wild type pfcrt alleles. This rules
out the possibility that the sensitive isolates originated
from a simple back mutation at the crucial position 76
of the pfcrt gene in former resistant parasites and is
consistent with the results of others [3-5]. The impli-
cation of this finding is that the wild type pfcrt allele
must have been reintroduced into the current popula-
tion through import from another geographic area, or
by reexpansion of sensitive parasites that were under
the detection level of previous investigations. However,
given the persistently high prevalence of the resistant
haplotypes the former possibility appears more likely.
Chromosome 7 haplotype analysis of the three sensi-
tive monoinfections showed no conservation of micro-
satellite alleles. Comparison to the local resistant
population showed that one (isolate SP15) shared the
two microsatellites PE14D and B5M77 at the most
telomeric end of the analysed haplotype with the
dominant local resistant haplotypes. To estimate the
likelihood that the SP15 haplotype resulted from a
cross of a local resistant and a sensitive isolate, the
number of resistant parasites with the same PE14D
and B5M77 alleles as SP15 was quantified. Of the 172
haplotypes analysed in the study, 107 carried the
exactly same PE14D-7A11 microsatellite alleles as
SP15, suggesting that SP15 might represent a genetic
cross between a sensitive strain and a formerly resis-
tant strain of the local population.
Conclusions
The data presented in this manuscript show that four
years after the discontinuance of CQ as first-line ther-
a p yi nG a b o nt h ep r e v a l e n c eo ft h em u t a n tpfcrt allele
is still extremely high in the Lambaréné area. This
finding stands in marked contrast to a more
pronounced development towards CQS in some other
African countries. One possible explanation may be an
ongoing selection for the mutant pfcrt allele by AQ as
part of an artemisinin-based combination therapy. It
has repeatedly been proposed that CQ may return to
clinical use in the future. The results of this investiga-
tion and the result of others [6,7] sound a note of cau-
tion and clearly show that this can only be
contemplated in areas where the return of CQ sensitiv-
ity has clearly been demonstrated by molecular drug
sensitivity monitoring.
Additional material
Additional file 1: Primers and conditions for microsatellite PCR
amplification. Table of primer sequences and PCR cycling conditions
employed for microsatellite analysis
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